Rutgers University and Tel Aviv University (TAU) signed a memorandum of understanding that will further the collaboration between the two research universities and establish a presence by TAU at The Hub, a 550,000-square-foot, $665 million project in New Brunswick, NJ.
As a key player in developing and transforming innovators into entrepreneurs that improve people’s lives, Rutgers, The State University of New Jersey will expand its entrepreneurship training programming and further equip faculty and student researchers with the skills and strategy needed to transition their discoveries into technologies and products, as a partner in the newly created NSF I-Corps™ Hub: Northeast Region.
Leading experts at Rutgers and Tel Aviv Universities hosted a symposium centered on the coronavirus pandemic and the research, response and lessons learned through the COVID-19 outbreak in the sister states of New Jersey and Israel.
A novel base editing technology invented at Rutgers, with the potential to be used for the creation of new cell and gene therapies, will be made available to researchers worldwide through an exclusive partnership with the Horizon Discovery Group.
Rutgers University signs two agreements with Santhera Pharmaceuticals to advance pioneering research for the treatment of congenital muscular dystrophy. The agreements complement ongoing research of Peter Yurchenco, professor at Rutgers Robert Wood Johnson Medical School and a pioneer in a novel gene therapy approach for the treatment of LAMA2-deficient congenital muscular dystrophy.